Guided Therapeutics (GTHP) Operating Leases (2019 - 2025)
Historic Operating Leases for Guided Therapeutics (GTHP) over the last 7 years, with Q3 2025 value amounting to $76000.0.
- Guided Therapeutics' Operating Leases fell 5730.34% to $76000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $76000.0, marking a year-over-year decrease of 5730.34%. This contributed to the annual value of $155000.0 for FY2024, which is 3699.19% down from last year.
- Latest data reveals that Guided Therapeutics reported Operating Leases of $76000.0 as of Q3 2025, which was down 5730.34% from $104000.0 recorded in Q2 2025.
- Guided Therapeutics' Operating Leases' 5-year high stood at $419000.0 during Q2 2021, with a 5-year trough of $76000.0 in Q3 2025.
- Its 5-year average for Operating Leases is $259157.9, with a median of $267000.0 in 2022.
- As far as peak fluctuations go, Guided Therapeutics' Operating Leases surged by 408000.0% in 2021, and later plummeted by 5730.34% in 2025.
- Quarter analysis of 5 years shows Guided Therapeutics' Operating Leases stood at $325000.0 in 2021, then changed by 0.0% to $325000.0 in 2022, then decreased by 24.31% to $246000.0 in 2023, then crashed by 36.99% to $155000.0 in 2024, then plummeted by 50.97% to $76000.0 in 2025.
- Its Operating Leases stands at $76000.0 for Q3 2025, versus $104000.0 for Q2 2025 and $130000.0 for Q1 2025.